Research On the Identification of Novel Antigens and The Optimization of Therapeutic Strategies in Cancer Immunotherapy Through Single-Cell Sequencing

Peixuan Li

Zhejiang University, Hangzhou, China

* Corresponding Author Email: Peixuan.22@intl.zju.edu.cn

Abstract. With the advancement of single-cell sequencing, we are now capable of analyzing the heterogeneity within tumors with increased precision, revealing the complex interactions between the tumor microenvironment and immune cell subgroups. Studies mentioned in the articles demonstrate significant cell heterogeneity in various cancers at genomic, transcriptomic, and proteomic levels. In particular, single-cell technologies aid in identifying cell-type-specific genetic lineage effects, for example, in the context of influenza infection and T cell surveillance. Current study focuses on the application of single-cell sequencing in cancer immunotherapy and the exploration of novel antigen identification and optimization of therapeutic strategies. The introduction of new strategies, such as the refinement of electrochemical immuno-sensors, synthesis of novel small molecule drugs, and optimized detection of genetic mutations, contributes collectively to the accurate identification of tumor markers and innovative development of therapeutic methods. The integration of treatment schemes and patient survival analysis further guides the implementation of personalized medicine. In summary, the application of single-cell sequencing and its integration with the optimization of therapeutic strategies promises revolutionary advancements in the field of cancer immunotherapy.

Keywords: Single-cell sequencing; Cancer immunotherapy; Tumor markers; Therapeutic strategy optimization; Cellular heterogeneity.

1. Introduction

In recent years, the application of single-cell sequencing technology in precision medicine has gained increasing attention, particularly for its significant potential in cancer immunotherapy. This technology has uncovered the cellular heterogeneity within the tumor microenvironment and the complex interactions between tumors and immune cells, providing new avenues for the identification of novel tumor antigens and the optimization of immunotherapy strategies. However, despite some progress, challenges remain in effectively translating these research findings into clinical treatment strategies [1]. Current study integrates the latest advancements in single-cell sequencing technology within cancer immunotherapy, explores its applications and potential in the identification of new antigens and the optimization of treatment strategies, and proposes future research directions. The aim is to facilitate the translation of theoretical research into clinical practice, thereby advancing the development and innovation of cancer immunotherapy.

2. Single-cell sequencing technology and its application in tumor immunotherapy

2.1. Overview of single-cell sequencing technology

Single-cell sequencing technology can accurately quantify the gene expression of individual cells and reveal their heterogeneity at the molecular level. In tumor immunotherapy, the use of single-cell sequencing technology allows for the identification of novel tumor antigens and the optimization of immunotherapy strategies [1]. Single-cell sequencing technology provides detailed knowledge of the function and status of different immune cells in the tumor microenvironment by meticulously resolving expression profiles in different cell states [2,3]. For example, by analyzing single-cell data

in tumor-draining lymph nodes, it is possible to observe how the tumor microenvironment affects immune regulation and metabolic shifts in lymph node cells, which is critical for designing immunotherapeutic strategies that target tumor escape[2].

With the integration of single-cell technologies with computational biology, more powerful tools can be applied to analyze and integrate single-cell data from different sources and types.Mohammad Lotfollahi et al. proposed a migration-learning-based single-cell data integration method to more flexibly adapt to the variability between data generated under different experimental conditions, which is essential for a cellular-level understanding of antigen presentation and a nuanced understanding of cell-to-cell communication[4]. Considerations of experimental and bioinformatics approaches have also shown their importance in cancer applications of single-cell genomics, which help researchers to better process data and derive meaningful biological insights from them, providing experimental support for cancer immunotherapy optimization [5].

2.2. Application of single-cell technology in the tumor immune microenvironment

Single-cell sequencing technology provides a new perspective for a deeper understanding of the tumor immune microenvironment. This technology allows observation and analysis at the individual cell level, enabling researchers to identify cellular subpopulations and molecular signals that have key roles in the tumor immune response. For example, Li revealed immune regulation and metabolic switching in tumor-draining lymph nodes through single-cell analysis, which helped to understand how the tumor immune microenvironment contributes to tumor survival and spread [2]. In addition, single-cell techniques can reveal complex interactions between tumors and the immune system, and a study by Johnson elucidated the role of the tumor microenvironment in lung cancer progression, which provided crucial information for optimizing targeted therapies [1]. Further, Pappalardo utilized single-cell technology to define T-cell surveillance in human cerebrospinal fluid, which provided a new way to identify potential therapeutic targets [3].

Integrated learning and transfer learning techniques also play a key role in enabling single-cell data analysis. For example, Lotfollahi performed single-cell integration by transfer learning, an approach that allows knowledge transfer between different datasets and reduces the need for separate sequencing for new samples [4]. Also, single-cell transcriptomics studies have shown cell-type specificity in differences in gene expression and response to viral infection, as noted in the study by Randolph [6]. These findings further emphasize the need to focus on cellular heterogeneity in cancer immunotherapy and the potential impact of an individual's genetic background on treatment efficacy.

Finally, Tan summarized experimental and bioinformatics considerations of single-cell genomics in cancer applications, highlighting the importance of data analysis and interpretation [5]. This demonstrates the need for new experimental approaches in the research and development of tumor immunotherapies, not only to enhance the quality and depth of single-cell analyses, but also for innovations in bioinformatics approaches to cope with the complexity of the data. Such advances will facilitate the identification of new antigenic targets and provide a scientific basis for the optimization of tumor immunotherapy strategies.

2.3. Overcoming Challenges and Future Directions in Single-Cell Sequencing Technology

Although single-cell sequencing (SCS) technology has made significant progress in the study of cancer immunotherapy, challenges remain. For example, in the study of immunoregulatory processes and metabolic transitions, SCS technology requires a deeper understanding of the complex tumor microenvironment and the interactions between tumor-draining lymph nodes[2]. To overcome this challenge, researchers have developed new algorithms and models, such as query to reference exploration of single-cell integration through transfer learning[4].This approach enables the integration of single-cell data from different technological platforms and experimental conditions, facilitating comparative analysis across samples and conditions.

In the study of the effect of gene progenitors on the response to viral infection, the use of single-cell RNA sequencing (SCRNA-seq) technology demonstrated that although gene progenitor effects

are widespread, they are strongly dependent on specific cell types[6]. This finding provides a new perspective on the targeting of cancer immunotherapies, suggesting the need to consider cell type-specific molecular features when designing therapeutic strategies.

In addition, single-cell analyses of the tumor microenvironment, such as those seen in lung cancer progression studies, reveal how the tumor microenvironment drives disease progression by influencing immune cell function[1].Research breakthroughs in this area offer the potential to deepen our understanding of the characteristics of the tumor immune microenvironment and its disease mechanisms.

Experimental and bioinformatics considerations are crucial when conducting single-cell genomic studies.Tan emphasized the need for careful handling of sample preparation, data generation, and downstream analyses when applying SCS data in cancer to ensure the reliability of the data and the accuracy of interpretation[5] .

Future studies can pin their hopes on the continuous optimization and development of interpretive models for SCS techniques to identify novel antigens more effectively and optimize cancer immunotherapy strategies. By integrating interdisciplinary approaches from biomedicine and computational biology, we will be able to deepen our insights into the interactions between cancer and the immune system and provide more personalized treatment plans for patients.

3. New Strategies and Technologies in Immunotherapy and Tumor Marker Identification

3.1. Next-generation sequencing technologies in microbial markers

In cancer immunotherapy, accurate identification of microbial markers is essential for early detection of disease and optimization of treatment strategies. Next-Generation Sequencing (NGS), as a powerful tool, provides unprecedented depth and resolution for microbial marker studies. in their study, Carter demonstrated how NGS technology can be used in microbial population studies to reveal complex microbe-host interactions, and provide a powerful tool for the identification of cancer-related markers[7]. In addition, Mannakee improved the accuracy of low-frequency variant detection in NGS through a statistical approach, which is crucial for capturing the signals of small mutations in early cancer processes. These variant signals, which are distinct from normal cells, may be candidates for future immune targets[8].

NGS technology also facilitates the exploration of non-coding regions, as shown by Rongrong Li in his study, CD19+ extracellular vesicles can be used as cancer markers, which increases our knowledge of potential markers such as non-coding RNAs in the tumor microenvironment[9].

Further, the electrochemical immunosensor developed by Martínez Rojas offers the possibility of low-cost, highly sensitive detection of specific cancer markers, and the implementation of this approach may benefit from the ability of NGS technology to recognize unique markers at the cellular level[10] .

Despite the availability of various compounds for immunomodulation to prevent or treat cancer, as studied by Zhang, NGS plays an irreplaceable role for the recognition of novel antigens and the optimization of immune strategies[11]. Especially in today's advancing personalized medicine, NGS technology provides us with a powerful means to gain a deeper understanding of the genetic heterogeneity of tumors, to mine new antigenic targets, and to make precise adjustments to treatment regimens.

3.2. Immunosensors and specific tumor marker detection

In cancer immunotherapy, the identification of specific tumor markers is important for precision medicine and patient prognosis. Immunosensor technology, as an emerging detection tool, provides a new perspective for tumor marker identification.Martínez Rojas, Francisco Javier developed a highly sensitive electrochemical immunosensor based on specific cancer biomarkers[10]. This sensor

utilizes the binding reaction of specific antibodies to tumor markers and achieves rapid detection of the markers through electrochemical signal changes. The sensitivity and specificity of this method shows great promise in the laboratory setting and is expected to be used for clinical diagnostics.

In addition, there is, with the rapid development of single-cell sequencing technology, researchers are beginning to explore its potential for identifying emerging antigens in cancer immunotherapy. Single-cell sequencing can reveal the heterogeneity of different cells within a tumor, providing a basis for fine-tuned treatment. For example, a study by Rongrong Li established a novel tumor marker assay for immunotherapy by analyzing CD19~+ extracellular vesicles[9]. By analyzing the interaction between tumor cells and the immune system at the single-cell level, this method not only identifies new tumor-associated proteins, but also provides guidance for subsequent therapeutic strategies.

At the same time, the methods for analyzing sequencing data are constantly being improved.Carter, Kyle and Brian K. Mannakee have conducted in-depth studies on the statistical methods of next-generation sequencing (NGS) technology in microbiome studies and low-frequency variant detection in tumor genomes, respectively[7,8]. These methods help to identify novel antigens of low abundance in tumors more accurately and may become a beneficial weapon for future cancer immunotherapy.

Taken together, these studies show that the detection efficiency and accuracy of specific tumor markers can be greatly improved by combining advanced methods such as electrochemical immunosensors with single-cell sequencing technology. The combination of these strategies and technologies is expected to drive the identification of new antigens and optimization of therapeutic strategies in the field of cancer immunotherapy.

3.3. Advances in the study of small molecule immunomodulators in cancer therapy

In the search for more effective cancer immunotherapy strategies, the development of small molecule immunomodulators has become a research focus. These molecules are able to improve the tumor microenvironment by modulating the body's immune system, thus enhancing the recognition and killing ability of immune cells on tumor cells. Zhang mentioned in their study that small molecule immunomodulators can inhibit tumor growth by affecting the expression of immune-suppressing factors in the tumor microenvironment or by activating the tumor-specific T-cell response[11]. This provides a new perspective that activating or restoring a patient's own immunity through small molecule drugs is a potential way to achieve precise and personalized treatment.

It is also important to mention that based on the characteristics of small molecule drugs, such as their wide distribution and controllability in vivo, their application in cancer immunotherapy also encompasses a wide range of possibilities for drug design and functional optimization. For example, Martínez Rojas investigated and developed small molecule probes targeting specific cancer markers using chemical methods for enhancing the recognition of tumor cells in patients[10]. This advancement suggests that refined small molecule design could make it an effective homogenization tool for targeted therapy.

In practice, the use of small molecules has also shown a tendency to be combined with conventional immunotherapy. Zeytün synthesized novel thiazole derivatives and evaluated their antitumor activity, and found that such small molecules were able to efficiently modulate the function of immune cells under specific conditions, thus enhancing their ability to fight against tumor cells. This not only improves our understanding of the mechanism of the role of small molecules in regulating the immune response to tumors, but also opens up new directions for therapeutic drug development[12].

4. Treatment Options and Patient Survival Analysis in Immunotherapy

4.1. Immune checkpoint blocker treatment strategies and survival analysis

In the field of cancer immunotherapy, the use of immune checkpoint blockers has become an important therapeutic tool. These drugs activate the patient's own immune system to attack the cancer

cells by deregulating the tumor's inhibitory effect on the T-cells.Paydary conducted a study on patients treated with immune checkpoint blockers and found that there was a strong association between the demographic characteristics of the patients, their clinical symptoms, and their laboratory markers and their overall survival rate[13]. Their study suggests that some biomarkers, such as white blood cell counts and LDH levels, may be instructive in predicting treatment efficacy and patient prognosis. In addition, Govindarajan suggested that a high-throughput precision medicine approach for high-grade plasma ovarian cancer could reveal tumor heterogeneity and optimize individualized treatment plans[14]. Their study focused on using technologies such as single-cell sequencing to identify novel therapeutic targets and provide finer-grained tumor characterization to guide strategy development for immunotherapy.

In specific cancer treatments, such as sarcoma treatment, Kelly MD highlighted the emerging role of immunotherapy and noted that personalized therapy development incorporating single-cell sequencing technologies can help to better understand and respond to the immune environment of sarcomas[15]. For these highly heterogeneous tumors, identifying and targeting their respective novel antigens for therapy may significantly improve treatment success. In addition, Shepard proposed the targeting of chromosomal DNA with aggression probes, which could be used as a high-precision tool to detect specific variants in the tumor genome, which in turn could help in the design of more targeted therapeutic strategies[16].

Taken together, these studies show that the identification of new immune markers and optimization of therapeutic strategies through single-cell sequencing plays a key role in the design of individualized immunotherapy regimens and survival analysis. Understanding the cellular level heterogeneity of patients and changes in the immune microenvironment has irreplaceable significance in optimizing therapeutic strategies, improving therapeutic efficacy, and predicting survival.

4.2. Application of high-throughput technologies in immunotherapy protocols

In the field of tumor immunotherapy, high-throughput single-cell sequencing has become a powerful tool for optimizing therapeutic strategies and deepening the understanding of pathomechanisms. In a study by Govindarajan , it was suggested that high-throughput sequencing technology is capable of performing precision medicine in high-grade plasma ovarian cancer[14]. This approach can identify the heterogeneity of the patient's cancer cells and the composition of immune cells in the microenvironment, providing a strong scientific basis for individualized treatment strategy development. Similarly, Kelly emphasized the potential role of immunotherapy in the treatment of sarcoma and mentioned that through high-throughput technologies, researchers can optimize the use of immune checkpoint inhibitors and advance therapeutic strategies through a deeper understanding of the properties of immune cells in the tumor microenvironment [15].

The process of precision medicine is also closely linked to the analysis of patient survival. Paydary in their study of patients treated with immune checkpoint inhibitors explored the association of patient demographics, clinical and laboratory parameters with overall survival[13]. This type of analysis is important for assessing treatment efficacy and guiding the optimization of future treatment regimens. In addition, high-throughput technologies are not limited to analyzing heterogeneity at the gene or protein level; a study by Shepard demonstrated that even Invader probe targeting techniques for chromosomal DNA can provide important information for understanding cancer biology and the mechanisms by which responses respond to immunotherapy[16].

To summarize previous findings, high-throughput single-cell sequencing technologies allow researchers to meticulously reveal the immune escape mechanisms of tumors and the activation status of immune cells at the molecular level, which can lead to the identification of new tumor-associated antigens and further influence the design and optimization of therapeutic regimens. These techniques all show great potential for increasing the precision of treatment and improving patient prognosis. Future research needs to make finer use of these techniques to detail the complex interactions in the tumor microenvironment and continue to drive the development of personalized medicine.

4.3. Challenges and Advances in Cancer Immunotherapy in Osteosarcoma

The advent of immune checkpoint inhibitors has brought hope to many cancer patients, especially those who have not been effectively helped by conventional therapies. However, progress in applying immunotherapy has been relatively slow in osteosarcoma, a malignant tumor, mainly due to its high heterogeneity and difficulty in identifying novel antigens[15]. Identification of novel and effective tumor-associated antigens can provide important molecular targets for targeted therapy and vaccine development. The application of single-cell sequencing technology has provided new insights into the tumor microenvironment and its complex effects on immune cells.

Patient clinical and biomarkers are key parameters when assessing the efficacy of immunotherapy. For example, Paydary in his study highlighted the correlation between demographic characteristics, clinical and laboratory parameters and overall survival of patients treated with immune checkpoint inhibition[13]. In addition, Shepard has further enhanced our ability to understand and characterize cancer biomarkers at the molecular level by targeting chromosomal DNA with the “Invader Probe”, which provides new directions for future immunotherapy strategies[16].

In order to optimize the outcome of osteosarcoma patients, high-throughput approaches such as those proposed by Govindarajan provide a blueprint for precision medicine in high-grade plasma ovarian cancer[14]. With such techniques, personalized treatment strategies can be tailored to the tumor characteristics of individual patients, thereby improving efficacy and reducing unwanted side effects.

Although the above studies have demonstrated the potential of single-cell sequencing in identifying novel antigens and optimizing therapeutic regimens, in the field of osteosarcoma, there are many challenges to translating these findings into clinical practice. For example, the high degree of tumor heterogeneity, which makes a single therapeutic strategy often unable to meet the needs of all patients, and the current incomplete understanding of novel antigens and associated immune escape mechanisms have combined to limit the widespread use of immunotherapeutic strategies. Therefore, future research needs to focus not only on the identification of antigens at the single-cell level, but also on the complete tumor microenvironment, in order to achieve more precise and targeted interventions.

5. Tumor Genetics and Genomic Research

5.1. Comprehensive taxonomic analysis of tumor genomes

In terms of comprehensive taxonomic analysis of tumor genomes, studies have shown a genomic basis for the distribution and changes of RNA modifications in cancer genomes [17]. This finding has potential implications for identifying novel tumor antigens and optimizing cancer immunotherapy strategies. Specifically, by utilizing single-cell sequencing technology, researchers are able to more accurately observe genomic heterogeneity within individual cells, which is critical to unraveling the mechanisms by which tumors develop and evade immune surveillance. In addition, single-cell technology has revealed the link between aberrant RNA modifications and the evolution of cancer cell clones and the development of personalized cancer therapies.

There are also other factors to consider, and the development of single-cell sequencing technology has provided new perspectives on tumor genomic research.Saremi pointed to the effectiveness of genomic approaches in their study of the evolutionary consequences of declining population sizes in species[18]. Although Saremi's study focused on population genomes, his approach and conclusions also provide insights into understanding the dynamic evolution of tumor cell populations, as tumors can also be considered as a population of cells whose genetic and phenotypic diversity directly affects the success of therapies.

The application of personalized strategies in tumor genetics and genomic studies also enhances the accuracy of therapies. Echoing this, Tong discussed the benefits of personalized mobile marketing strategies, and although the domain of this study was commercial marketing, the concepts therein

regarding personalized strategies can be extended to cancer therapies[19]. By integrating the genomic information of patients and the single-cell sequence characteristics of cancer cells, more personalized therapeutic strategies can be designed to improve treatment efficacy and reduce side effects.

To summarize the previous discussion, single-cell sequencing technology has significantly advanced the study of comprehensive taxonomic analysis of tumor genomes. By gaining a deeper understanding of the genetic heterogeneity within tumors, researchers can more effectively identify new tumor antigens and optimize immunotherapeutic strategies for different tumor types.

5.2. Impact of Species Genome Evolution on Tumor Genetics

In the study of tumor genetics, the understanding of species genome evolution is crucial for revealing the genetic basis of tumor development. In a study led by the PCA WG Transcriptome Core Group, a systematic genomic analysis of alterations in cancer RNA was conducted [17]. This study involved the analysis of large-scale cancer genomic data, which revealed important alterations at the RNA level, which is particularly important for understanding how species acquire highly specific tumor genetic traits during long-term evolution. In addition, Saremi provided insights into how to understand at the genomic level how evolutionary changes have affected cancer genetics by studying the evolutionary consequences of population decline[18]. Their study suggests that changes in population size induce changes in genome structure that may play a role in the genetic background of tumors.

During the evolution of a species' genome, changes in gene frequencies due to environmental stresses and stochastic events may be preserved due to drift or adaptive selection. These genetic changes accumulated during evolution may provide the molecular basis for some cancer susceptibility or resistance. For example, the clonal evolution of tumors is a dynamic process that mimics some aspects of species evolution, including the accumulation of mutations and the role of selective forces. Thus, the impact of species genome evolution on tumor genetics is multifaceted and encompasses patterns and processes of evolutionary genetics.

Understanding the role of species genome evolution in tumor formation may have potential implications for the development of therapeutic strategies for specific cancers. For example, monitoring patterns of genome evolution could assist us in tailoring personalized mobile marketing strategies, and similarly, these strategies could guide us on how to administer immunotherapies in a more targeted manner and how to optimize oncology treatments at the individual level[19].

To summarize, species genome evolution has a significant impact on tumor genetics, and they play a decisive role in the genetic context of tumor development. Through in-depth analysis of these evolutionary processes and their relationship to cancer formation, we can not only better understand the origin and evolution of tumors, but also provide new ideas and strategies for cancer therapy.

5.3. Personalized Tumor Genetics Research Methods

Individualized tumor genetics research using single-cell sequencing technology has become an important advancement in the field of scientific research. Among the representative studies in this area, the PCAWG Transcriptome Core Group, in collaboration with a number of scientists, has used large-scale computational resources and advanced data mining techniques to gain a deeper understanding of RNA variations in tumors and their basis at the genetic level [17]. In addition, Saremi highlighted through their study the consequences of understanding population decline on genome evolution, an approach that also provides a new line of thought for studying individualized tumor genetics[18]. In addition, personalization strategies are not limited to disease treatment, as Siliang Tong pointed out in their study, the concept of personalization has also been proposed for strategies in the field of mobile marketing, which provides a comparative perspective between different fields for the study of personalized genetics research approaches in oncology treatment[19].

When exploring optimal individualized oncogenetic research approaches, scientists usually face two main challenges: how to accurately identify new tumor antigens from massive genomic data, and how to optimize therapeutic strategies to improve the success rate of clinical applications. To address

the first challenge, the application of single-cell sequencing technology allows for the resolution of subtle differences in gene expression at the individual cell level, which is critical for the discovery of new antigens that can be utilized in immunotherapy. In response to the second challenge, the optimization of personalized therapeutic strategies requires a comprehensive consideration of the unique genomic characteristics of patients as well as the molecular heterogeneity of tumors, which requires researchers not only to accurately identify therapeutic targets, but also to understand how these targets may generate different therapeutic responses in different individuals [17].

To summarize the previous discussion, the personalized oncogenetic research approach aims to advance cancer immunotherapy through precision analysis, and single-cell sequencing technology has opened up new possibilities in this field, allowing individual differences at the genomic level to be explicitly identified, which in turn facilitates personalized optimization of therapeutic strategies. As the technology continues to evolve and deepen, there is reason to believe that significant breakthroughs will continue to be made in this field.

6. Conclusion

In recent years, significant progress has been made in cancer immunotherapy, particularly through the application of single-cell sequencing technology, which has deepened our understanding of the tumor microenvironment and immune responses. This technology has revealed the heterogeneity and dynamic changes of cell subpopulations within the tumor immune microenvironment, providing new possibilities for the identification of novel antigens and the optimization of therapeutic strategies.

Research has shown that single-cell sequencing can identify the interactions between tumor cells and immune cells, findings that hold promise for translating into personalized immunotherapy approaches. However, challenges remain in integrating and analyzing large-scale single-cell data, prompting researchers to improve statistical methods for a better understanding of the genetic characteristics of cancer. Additionally, single-cell sequencing has led to the discovery of new tumor biomarkers that aid in early diagnosis, targeted therapy design, and treatment monitoring.

Future research trends include advances in multi-modal single-cell analysis techniques to drive the development of precision immunotherapy strategies; the evolution of high-throughput data analysis algorithms utilizing artificial intelligence to identify new biomarkers; the identification of novel antigens through single-cell sequencing for personalized immunotherapy; in-depth study of the regulatory mechanisms of the tumor microenvironment to develop combination therapies; and the use of single-cell data combined with clinical information to predict individualized immunotherapy responses.

Research recommendations include deepening the study of cellular heterogeneity and the immune microenvironment, improving antigen prediction algorithms, integrating personalized medicine with immunotherapy, discovering new immune checkpoint molecules, constructing cell-cell interaction networks, and promoting data sharing and collaborative research. These directions will help advance the frontiers of cancer immunotherapy research, leading to more personalized and effective treatment strategies.

References

[1] Osipov A, Saung MT, Zheng L, Murphy AG. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J Immunother Cancer. 2019.

[2] Li YL, Chen CH, Chen JY. Single-cell analysis reveals immune modulation and metabolic switch in tumor-draining lymph nodes[J]. OncoImmunology, 2020.

[3] Tong S, Luo X, Xu B. Personalized mobile marketing strategies[J]. Journal of the Academy of Marketing Science, 2020.

[4] Lotfollahi M, Naghipourfar M, Luecken MD. Query to reference single-cell integration with transfer learning[J]. bioRxiv, 2020.

[5] Li C, Sun YD, Yu GY, Cui JR, Lou Z, Zhang H, Huang Y, Bai CG, Deng LL, Liu P, Zheng K, Wang YH, Wang QQ, Li QR, Wu QQ, Liu Q, Shyr Y, Li YX, Chen LN, Wu JR, Zhang W, Zeng R. Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell. 2020 Nov 9;38(5):734-747.e9.

[6] Randolph HE, Mu Z, Fiege JK. Single-cell RNA-sequencing reveals pervasive but highly cell type-specific genetic ancestry effects on the response to viral infection[J]. bioRxiv, 2020.

[7] Carter KM, Matthew C. Novel Methods for Next-Generation Sequencing Data with Applications in Microbiome Studies[D]. The University of Arizona, 2020.

[8] Mannakee B. Statistical Methods for Improving Low Frequency Variant Calling in Cancer Genomics[D]. The University of Arizona, 2020.

[9] Govindarajan M, Wohlmuth C, Waas M. High-throughput approaches for precision medicine in high-grade serous ovarian cancer[J]. J Hematol Oncol, 2020.

[10] Saremi NF. A Genomic Approach to Studying the Evolutionary Consequences of Population Declines[D]. University of California, Santa Cruz, 2020.

[11] Tan JHJ, Kong SL, Tai JA. Experimental and bioinformatics considerations in cancer application of single cell genomics[J]. Comput Struct Biotechnol J, 2020.

[12] Schafflick D, Xu CA, Hartlehnert M, Cole M, Schulte-Mecklenbeck A, Lautwein T, Wolbert J, Heming M, Meuth SG, Kuhlmann T, Gross CC, Wiendl H, Yosef N, Meyer zu Horste G. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nature Communications, 2020.

[13] Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee JJ, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer[J]. 2020.

[14] Kelly CM, Klemen ND, Bartlett EK. The emerging role of immunotherapy for the treatment of sarcoma[J]. Journal of Surgical Oncology, 2020.

[15] Martínez Rojas FJ. Desarrollo de un Inmunosensor Electroquímico para la Detección de Biomarcador Específico de Cáncer[D]. Pontificia Universidad Católica de Chile (Chile), 2020.

[16] Johnson AM. The Role of the Tumor Microenvironment on the Progression of Lung Cancer[D]. University of Colorado Denver, Anschutz Medical Campus, 2020.

[17] Guenther DC, Anderson GH, Karmakar S, Anderson BA, Didion BA, Guo W, Verstegen JP, Hrdlicka PJ. Invader probes: Harnessing the energy of intercalation to facilitate recognition of chromosomal DNA for diagnostic applications. Chemical Science, 2015.

[18] Altıntop MD, Zeytun E, Dilek EZ. Yeni Tiyazol Türevlerinin Sentezi ve Antikanser Etki Çalışmaları[D]. Anadolu University (Turkey), 2020.

[19] Zou W, Luo X, Gao M, et al. Optimization of Cancer Immunotherapy on the Basis of PD-L1 Distribution and Function[D]. British Journal of Pharmacology, 2023.